Viracta Therapeutics to Present at Upcoming Investor Conferences

Ein Business-Meeting (Symbolbild). © gilaxia / E+ / Getty Images

PR Newswire

SAN DIEGO, Nov. 1, 2021

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present and host one-on-one meetings at the following upcoming investor conferences:

Credit Suisse 30^th Annual Healthcare Conference (virtual)

Conference Dates:

November 8 – 12, 2021

Presentation Date:

November 11, 2021

Presentation Time:

ARIVA.DE Börsen-Geflüster

Kurse

Viracta Therapeutics

0,62 €

-3,88%

1:50 PM ET

Format:

Corporate presentation

Jefferies London Healthcare Conference (in-person)
Conference Dates:	November 16 – 17, 2021
Presentation Date:	November 17, 2021
Presentation Time:	10:40 AM GMT/ 5:40 AM ET
Format:	Corporate presentation

Piper Sandler 33^rd Annual Healthcare Conference (virtual)
Conference Dates:	November 29 – December 2, 2021
Presentation Available:	November 22, 2021, at 10:00 AM ET
Format:	Corporate presentation

Evercore ISI 4^th Annual HealthCONx Conference (virtual)
Conference Dates:		November 29 – December 2, 2021
Presentation Date:		December 2, 2021
Presentation Time:		3:55 PM ET
Format:		Fireside chat

A live webcast of each of the presentations will be available under "Events and Webcasts" in the Investors section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts. Replays of each webcast will be archived on the Viracta website for at least 30 days following the presentation.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive (EBV⁺) lymphoma and one Phase 1b/2 trial in patients with EBV⁺ nasopharyngeal carcinoma and other EBV⁺solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers. For additional information please visit www.viracta.com.

Investor Relations Contact:

Ashleigh Barreto
Head of Investor Relations and Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-upcoming-investor-conferences-301413256.html

SOURCE Viracta

Mehr Nachrichten zur Viracta Therapeutics Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.